The Medicines Company Announces Participation at 2015 European Society of Cardiology Congress in London, Will Present Cardiovascular Product Portfolio Results

The Medicines Company today announced it will present results of recent clinical studies from its cardiovascular product portfolio at the 2015 European Society of Cardiology (ESC) Congress in London, August 29 to September 2. The presentations at ESC 2015 will include a poster presentation of the Phase 1 results for ALN-PCSsc, a subcutaneously administered investigational RNAi therapeutic targeting PCSK9 being developed for the treatment of hypercholesterolemia. Alnylam Pharmaceuticals conducted this trial under a collaboration agreement with The Medicines Company and will present the results on Sunday, August 30 at 8:30 am British Standard Time (BST) (3:30 am Eastern Daylight Time (EDT)). Several posters and presentations focusing on The Medicines Company's novel intravenous antiplatelet agent, Kengreal™/Kengrexal™ (cangrelor) as well as the company's direct thrombin inhibitor, Angiomax®/Angiox® (bivalirudin), will also be presented during the meeting. Details for all activities are included in the grid below. Time Product Event Place SUNDAY 30TH 08:30 am BST Kengreal/Kengre xal POSTER P1497: Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study Poster Area - Agora 08:30 am BST Angiomax/Angi ox POSTER P1505: Access site versus non- access site bleeding in primary PCI: Incidence, impact on mortality and risk reduction according to antithrombin treatment. The EUROMAX trial Poster Area - Agora 08:30 am BST (03:30 am EDT) ALN-PCSsc POSTER P1761: A phase 1, randomized, placebo-controlled, single ascending and multiple dose study of subcutaneously administered ALN-PCSsc in subjects with elevated low density lipoprotein cholesterol. Alnylam will present these data. Poster Area - Agora 02:30 pm BST (09:30 am EDT) ALN-PCSsc CONFERENCE CALL: Joint telephone and webex conference call with our partner, Alnylam, to discuss ALN-PCSsc results See below for the call details MONDAY 31ST 14:54 pm BST Kengreal/Kengre xal PRESENTATION 4002: The effect of cangrelor and access site on ischemic and bleeding events: insights from CHAMPION- PHOENIX Chisinau - Village 6 15:47 pm BST Kengreal/Kengre xal MODERATED POSTER P4105: Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: the CHAMPION experience Moderated poster station - Poster Area - Agora TUESDAY 1st 10:34 pm BST Angiox/Angiom ax MODERATED POSTER P4992: 30 day clinical outcomes of bivalirudin vs heparin in the elderly patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention, a pooled analysis Moderated poster station - Poster Area 14:18 pm BST Angiox/Angiom ax RAPID FIRE ORAL SESSION 5813: Impact of acute infarct-related artery patency before PCI on 30 day outcomes in patients with ST-segment elevation myocardial infarction treated with primary PCI in the EUROMAX trial Victoria Park - The Hub 17:24 pm BST Angiox/Angiom ax HOTLINE IV ORAL SESSION 6004: Minimizing Adverse haemorrhagic events by TRansradial access site and systemic Implementation of angioX (MATRIX Antithrombin) London - Main Auditorium Conference Call ALN-PCSsc results will be discussed on a joint telephone and webex conference call with our partner, Alnylam, on August 30th at 2:30 pm BST (09:30 am EDT). This call is being webcast and can be accessed via Alnylam's website at www.alnylam.com as well as The Medicines Company's website at www.themedicinescompany.com. Domestic Dial-in: +1 (877) 312-7507 Ex-US Dial-in: +1 (631) 813-4828 Passcode for both Dial-in numbers: 18857833 Replay is available from 12:00 pm Eastern time following the conference call. To hear a replay of the call, dial +1 (855) 859-2056 (domestic) and +1 (404) 537-3406 (international). Passcode for both dial-in numbers is 18857833 In addition, the slides that will be used during the call can found on the event page of the Investor Relations section of our website at www.themedicinescompany.com. About KENGREXAL™ (cangrelor) In the European Union, cangrelor is marketed under the trade name KENGREXAL. KENGREXAL, a synthetic, small molecule, is indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor. Important Safety Information KENGREXAL™ is contraindicated in patients with significant active bleeding. KENGREXAL™ is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to cangrelor or any component of the product. Drugs that inhibit platelet P2Y12 function, including KENGREXAL™, increase the risk of bleeding. In CHAMPION PHOENIX, bleeding events of all severities were more common with KENGREXAL™ than with clopidogrel. Bleeding complications with KENGREXAL™ were consistent across a variety of clinically important subgroups. Once KENGREXAL™ is discontinued, there is no antiplatelet effect after an hour. The most common adverse reaction is bleeding.